MedTrace Logo

Anti Inflammatory Treatment of Hypertension

NCT04740840 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2021-02-05

No results posted yet for this study

Summary

To investigate the anti-inflammatory effect of amlodipine and levamlodipine in the treatment of hypertension

Conditions

Interventions

DRUG

Levamlodipine

According to the inclusion criteria of the trial, those who met the diagnosis of hypertension were randomly divided into the experimental group and the control group. The experimental group was treated with 2.5mg levamlodipine to lower blood pressure. Abdominal blood was emptying before the start of the trial and at the first and third month of medication.Data on CRP, TNF-α, IL-6, Lp-PLA2 and ATP were collected.

DRUG

Amlodipine

According to the inclusion criteria, patients who met the diagnosis of hypertension were randomly divided into the experimental group and the control group. The experimental group was given 5mg amlodipine to lower blood pressure. Fasting blood was collected before the trial and during the first and third months of treatment. CRP, TNF-α, IL-6, Lp-PLA2 and ATP data were collected.

Sponsors & Collaborators

  • First Hospitals affiliated to the China PLA General Hospital

    collaborator OTHER_GOV

  • Affiliated Hospital of North Sichuan Medical College

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-01
Primary Completion
2012-04-02
Completion
2015-05-02

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04740840 on ClinicalTrials.gov